Pacira BioSciences (NASDAQ:PCRX) versus Ultragenyx Pharmaceutical (NASDAQ:RARE) Financial Analysis

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares Ultragenyx Pharmaceutical and Pacira BioSciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$560.23 million	4.21	-$569.18 million	($5.94)	-4.11
Pacira BioSciences	$700.97 million	1.25	-$99.56 million	$0.45	45.29

Pacira BioSciences has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ultragenyx Pharmaceutical and Pacira BioSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.95%	-414.17%	-43.66%
Pacira BioSciences	2.99%	12.82%	6.57%

Insider & Institutional Ownership

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Ultragenyx Pharmaceutical has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Ultragenyx Pharmaceutical and Pacira BioSciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1	1	16	0	2.83
Pacira BioSciences	1	2	3	0	2.33

Ultragenyx Pharmaceutical presently has a consensus price target of $72.29, suggesting a potential upside of 195.80%. Pacira BioSciences has a consensus price target of $30.75, suggesting a potential upside of 50.88%. Given Ultragenyx Pharmaceutical’s stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Pacira BioSciences.

Summary

Pacira BioSciences beats Ultragenyx Pharmaceutical on 10 of the 14 factors compared between the two stocks.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

About Pacira BioSciences

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.